Hx009 is a humanized bispecific antibody fusion protein targeting the immunoregulatory checkpoint receptors PD-1 and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing, and antineoplastic activities. It exhibits anti-tumor effects in patients with advanced malignancies. MW: 173.16 KD.

Istiratumab is a fully human tetravalent bispecific antibody that binds to and co-inhibits IGF-1R and the epidermal growth factor family of receptor tyrosine kinases B3 (ErbB3), with potential anti-tumor activity. MW: 199.64 KD.

Glofitamab is a T-cell–engaging bispecific antibody that targets CD3 and CD20, demonstrating significant antitumor activity and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). It works by binding to CD20 on B cells and CD3 on T cells, promoting T-cell-mediated lysis of malignant B cells. MW: 170.28 KD.

Elranatamab-bcmm is a bispecific T-cell engager (BiTE) monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA), promoting the recruitment and activation of T cells to effectively eliminate malignant myeloma cells. It is FDA-approved for the treatment of adults with relapsed or refractory multiple myeloma. MW: 145.44 KD.

Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung […]

Tqb2858 is a bifunctional fusion protein consisting of a monoclonal antibody targeting programmed death ligand 1 (PD-L1) fused with the extracellular domain of the transforming growth factor beta (TGF-β) receptor. It simultaneously neutralizes TGF-β on tumor cells and inhibits PD-L1 activity, exhibiting potential antineoplastic and immune checkpoint-modulating effects. MW: 178.22 KD.

Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.

Epcoritamab is a bispecific IgG1 antibody that targets CD3 and CD20, exhibiting strong T-cell-mediated cytotoxic activity against CD20+ malignant B cells. It is used in the treatment of adults in relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after ≥2 lines of systemic treatment. MW: 145.26 […]

Duligotuzumab is a dual-action humanized IgG1 antibody that blocks ligand binding to the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). By inhibiting these interactions, it disrupts signalling from all ligand-dependent HER dimers and induces antibody-dependent cell-mediated cytotoxicity. It exhibits enhanced efficacy in EGFR inhibitor-resistant SCCHN and NSCLC models, with […]

Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD.